Key result
Perioperative aspirin and clonidine did not significantly affect the 1-year composite of death or nonfatal MI after noncardiac surgery (aspirin HR 1.00, P=0.948; clonidine HR 1.07, P=0.218).
Why the study?
Perioperative aspirin increased major bleeding and clonidine caused hypotension and bradycardia at 30 days after noncardiac surgery, but whether these complications produce harm at 1 yr remained unknown.
Does perioperative aspirin and/or clonidine reduce the composite of death or nonfatal myocardial infarction at 1 year in patients with or at risk of atherosclerosis undergoing noncardiac surgery?
RCT (n=10,010)
1:1:1:1
Does perioperative aspirin and/or clonidine reduce the composite of death or nonfatal myocardial infarction at 1 year in patients with or at risk of atherosclerosis undergoing noncardiac surgery?
Hazard Ratio: 1 (95% CI 0.89–1.12)
Absolute Event Rate: 11.8% vs 11.8%
p-value: p=0.948
Perioperative aspirin and clonidine do not provide long-term cardiovascular benefits at 1 year after noncardiac surgery, though aspirin may offer persistent benefit in patients with prior percutaneous coronary intervention.
Perioperative aspirin or clonidine confers no 1-year CV protection after noncardiac surgery; confirms neutral effect on death or MI.
BACKGROUND: The authors previously reported that perioperative aspirin and/or clonidine does not prevent a composite of death or myocardial infarction 30 days after noncardiac surgery. Moreover, aspirin increased the risk of major bleeding and clonidine caused hypotension and bradycardia. Whether these complications produce harm at 1 yr remains unknown. METHODS: The authors randomized 10,010 patients with or at risk of atherosclerosis and scheduled for noncardiac surgery in a 1:1:1:1 ratio to clonidine/aspirin, clonidine/aspirin placebo, clonidine placebo/aspirin, or clonidine placebo/aspirin placebo. Patients started taking aspirin or placebo just before surgery; those not previously taking aspirin continued daily for 30 days, and those taking aspirin previously continued for 7 days. Patients were also randomly assigned to receive clonidine or placebo just before surgery, with the study drug continued for 72 h. RESULTS: Neither aspirin nor clonidine had a significant effect on the primary 1-yr outcome, a composite of death or nonfatal myocardial infarction, with a 1-yr hazard ratio for aspirin of 1.00 (95% CI, 0.89 to 1.12; P = 0.948; 586 patients [11.8%] vs. 589 patients [11.8%]) and a hazard ratio for clonidine of 1.07 (95% CI, 0.96 to 1.20; P = 0.218; 608 patients [12.1%] vs. 567 patients [11.3%]), with effect on death or nonfatal infarction. Reduction in death and nonfatal myocardial infarction from aspirin in patients who previously had percutaneous coronary intervention at 30 days persisted at 1 yr. Specifically, the hazard ratio was 0.58 (95% CI, 0.35 to 0.95) in those with previous percutaneous coronary intervention and 1.03 (95% CI, 0.91to 1.16) in those without (interaction P = 0.033). There was no significant effect of either drug on death, cardiovascular complications, cancer, or chronic incisional pain at 1 yr (all P > 0.1). CONCLUSIONS: Neither perioperative aspirin nor clonidine have significant long-term effects after noncardiac surgery. Perioperative aspirin in patients with previous percutaneous coronary intervention showed persistent benefit at 1 yr, a plausible sub-group effect.
No takes yet. Share an insight, caveat, or question.
Sessler et al. (2020) conducted an RCT in Atherosclerosis risk in noncardiac surgery (n=10,010). Aspirin and Clonidine vs. Placebo was evaluated on Composite of death or nonfatal myocardial infarction at 1 year (HR 1.00, 95% CI 0.89-1.12, p=0.948). Perioperative aspirin and clonidine did not significantly affect the 1-year composite of death or nonfatal MI after noncardiac surgery (aspirin HR 1.00, P=0.948; clonidine HR 1.07, P=0.218).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: